JP
CLDX icon

John Paulson’s Celldex Therapeutics CLDX Stock Holding History

John Paulson’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,720
Closed -$251K – 103
2016
Q4 		$251K Hold
4,720
– – ﹤0.01% 100
2016
Q3 		$286K Hold
4,720
– – ﹤0.01% 93
2016
Q2 		$311K Hold
4,720
– – ﹤0.01% 85
2016
Q1 		$268K Buy
+4,720
New +$531K ﹤0.01% 93

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

John Paulson's CLDX Position: Q1 2017 in Review

John Paulson sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 4,720 shares — an estimated $251K sold.

John Paulson first reported a position in CLDX in Q1 2016 and held it in 4 quarters. The position peaked at $311K in Q2 2016. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • John Paulson reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • John Paulson sold 4,720 Celldex Therapeutics shares in Q1 2017, an estimated $251K.
  • John Paulson first reported a position in Celldex Therapeutics in Q1 2016 and held it in 4 quarters.
  • John Paulson's Celldex Therapeutics position peaked at $311K in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on Paulson & Co's 13F filing for Q1 2017, filed 15 May 2017.